Early Spironolactone Treatment Attenuates Heart Failure Development by Improving Myocardial Function and Reducing Fibrosis in Spontaneously Hypertensive Rats

Marcelo D.M. Cezar a Ricardo L. Damatto a Luana U. Pagan a Aline R.R. Lima a Paula F. Martinez b Camila Bonomo a Camila M. Rosa a Dijon H.S. Campos a Antonio C. Cicogna a Mariana J. Gomes a Silvio A. Oliveira-Jr b Daniella A. Blotta a Marina P. Okoshi a Katashi Okoshi a

aDepartment of Internal Medicine, Botucatu Medical School, Sao Paulo State University, UNESP
Botucatu, bFederal University of Mato Grosso do Sul, Campo Grande, Brazil

Key Words
Aldosterone antagonist • Cardiac remodeling • Collagen • Ventricular function • Papillary muscle • Spontaneously hypertensive rat

Abstract

Background: We evaluated the role of the aldosterone blocker spironolactone in attenuating long-term pressure overload-induced cardiac remodeling and heart failure (HF) in spontaneously hypertensive rats (SHR). Methods and Results: Thirteen month-old male SHR were assigned to control (SHR-C, n=20) or spironolactone (SHR-SPR, 20 mg/kg/day, n=24) groups for six months. Normotensive Wistar-Kyoto rats (WKY, n=15) were used as controls. Systolic blood pressure was higher in SHR groups and unchanged by spironolactone. Right ventricular hypertrophy, which characterizes HF in SHR, was less frequent in SHR-SPR than SHR-C. Echocardiographic parameters did not differ between SHR groups. Myocardial function was improved in SHR-SPR compared to SHR-C [developed tension: WKY 4.85±0.68; SHR-C 5.22±1.64; SHR-SPR 6.80±1.49 g/mm²; -dT/dt: WKY 18.0 (16.0–19.0); SHR-C 20.8 (18.4–25.1); SHR-SPR 28.9 (24.2–34.6) g/mm²/s]. Cardiomyocyte cross-sectional area and total collagen concentration (WKY 1.06±0.34; SHR-C 1.85±0.63; SHR-SPR 1.28±0.39 µg/mg wet tissue) were greater in SHR-C than WKY and SHR-SPR. Type 3 collagen expression was lower in SHR-C than WKY and unchanged by spironolactone. Soluble collagen, type I collagen, and lysyl oxidase did not differ between groups. Conclusion: Early spironolactone treatment decreases heart failure development frequency by improving myocardial systolic and diastolic function and attenuating hypertrophy and fibrosis in spontaneously hypertensive rats.
Introduction

Systemic arterial hypertension is a major cause of left ventricular hypertrophy and heart failure [1]. During long term pressure overload, stable cardiac hypertrophy develops and may progress to a decompensated state with left ventricular systolic and diastolic dysfunction and heart failure [2, 3].

Aldosterone, a mineralocorticoid hormone, mediates the renin-angiotensin-aldosterone system which is involved in several processes activated during pathological cardiac remodeling [4, 5]. Experimental studies have shown that aldosterone induces deleterious cardiovascular effects such as myocardial fibrosis, myocyte hypertrophy and apoptosis, oxidative stress, electrical remodeling, vascular injury, endothelial dysfunction, renal retention of sodium and water, and sudden death [6-10]. Furthermore, the aldosterone blockers spironolactone and eplerenone can attenuate structural, functional, and molecular changes in several models of cardiac injury [11-15]. In clinical settings, mineralocorticoid receptor antagonists reduce mortality and/or morbidity in patients with systolic dysfunction post-myocardial infarction [16] and in patients with reduced left ventricular ejection fraction and heart failure in New York Heart Association functional classes II to IV [17-19]. On the other hand, aldosterone blockade failed to reduce the incidence of cardiovascular morbimortality [20] or improve maximal exercise capacity, symptoms, or quality of life [21] in heart failure patients with preserved ejection fraction.

The spontaneously hypertensive rat (SHR) is a widely used experimental model for studying left ventricular hypertrophy and heart failure [2, 22]. It presents early arterial hypertension and left ventricular hypertrophy which evolves slowly to ventricular dysfunction and heart failure during maturity and senescence [3, 22, 23]. The transition from long-term compensated left ventricular hypertrophy to cardiac failure is characterized by marked myocardial fibrosis with an increase in collagen type I and collagen type I-to-III ratio [2, 24-27]. The potential beneficial role of aldosterone blockers in preventing or attenuating pressure overload-induced cardiac remodeling and heart failure development has not yet been completely clarified. In a previous work we observed that administering spironolactone from 16 to 22 months of age despite reducing mortality did not change cardiac remodeling [23]. At this stage SHRs probably presented advanced myocardial fibrosis thus preventing a reverse remodeling process. In this study we evaluated the effects of early spironolactone administration on heart failure development, left ventricular and myocardial function, and cardiac fibrosis in spontaneously hypertensive rats.

Materials and Methods

Experimental groups

Male spontaneously hypertensive rats (SHR) were purchased from the Central Animal House at Botucatu Medical School, UNESP. All animals were housed in a room under temperature control at 23 °C and kept on a 12-hour light/dark cycle. Food and water were supplied ad libitum. All experiments and procedures were approved by Botucatu Medical School Ethics Committee, UNESP, Botucatu, SP, Brazil.

Thirteen-month-old SHR were assigned to control group (SHR-C, n=20) or spironolactone treatment (SHR-SPR, n=24). Spironolactone was added to rat chow at 20 mg/kg/day for six months. Age-matched normotensive Wistar-Kyoto rats were used as controls (WKY, n=15). Rats were weighed weekly to adjust drug dosage.

Systolic arterial pressure was measured by the tail-cuff method at the start and end of the experiment. During euthanasia, we evaluated pathological evidence of heart failure such as pulmonary congestion (lungs-to-body weight ratio > 2 standard deviations above the mean for the WKY group) and right ventricular hypertrophy (right ventricle weight-to-body weight ratio > 0.8 mg/g) [28, 29].

Echocardiographic study

Echocardiographic evaluation was performed using a commercially available echocardiograph (General Electric Medical Systems, Vivid S6, Tirat Carmel, Israel) equipped with a 5 - 11.5 MHz multifrequency probe...
Total and soluble myocardial collagen was assessed using two colorimetric assays (QuickZyme Collagen Assay, Leiden, Netherlands) according to manufacturer instructions.
Serum creatinine and electrolytes concentration
Sodium, potassium, and magnesium serum concentrations were analyzed by flame photometry (FC-280, CELM) using a commercial standard solution. Creatinine concentration was quantified using the CELM SB-190 model spectrophotometer.

Western blotting analysis
Myocardial protein levels were analyzed by Western blotting according to a previously described method [38, 39] with specific type I collagen (anti-coll1a1, C-18, sc-8784-r; Santa Cruz Biotechnology, Santa Cruz, CA, USA), type III collagen (anti-collagen III, FH-7A, ab6310; Abcam, Cambridge, UK), and lysyl oxidase (anti-LOX, 1 ab60178; Abcam) antibodies. Protein levels were normalized to those of GAPDH (6C5, sc-32233, Santa Cruz Biotechnology). Muscle protein was extracted using Tris-Triton buffer (10 mM Tris pH 7.4, 100 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton X-100, 10% glycerol, 0.1% SDS, 0.5% deoxycholate). Supernatant protein content was quantified by the Bradford method. Samples were separated on a polyacrylamide gel and then transferred to a nitrocellulose membrane [40, 41]. After blockage, the membrane was incubated with primary antibody. The membrane was washed with TBS and Tween 20 and incubated with secondary peroxidase-conjugated antibody. Super Signal® West Pico Chemiluminescent Substrate (Pierce Protein Research Products, Rockford, USA) was used to detect bound antibodies.

Statistical analysis
Data are expressed as mean ± standard deviation or median and 25th and 75th percentiles. Comparisons between groups were performed by one way analysis of variance (ANOVA) followed by Bonferroni or Kruskal-Wallis followed by Dunn test (comparisons: SHR-C vs WKY and SHR-SPR vs SHR-C). Heart failure feature frequencies and mortality rate were assessed by the Goodman test. Statistical significance was accepted at p<0.05.

Results

Experimental groups and anatomical variables
During the experimental period, WKY, SHR-C, and SHR-SPR groups presented mortality rates of 0 %, 25 % and 12.5 %, respectively (p<0.05 SHR-C vs WKY). The mortality rate in SHR-SPR was intermediate but did not statistically differ from SHR-C. Heart failure feature frequencies in the SHR groups are shown in Table 1. In rats surviving to the end of the experimental period, SHR-SPR presented a statistically lower frequency of right ventricular hypertrophy. No WKY rat presented any evidence of heart failure.

Blood pressure and anatomical data are presented in Table 2. Initial body weight did not differ between groups. Final body weight was lower in both SHR groups than WKY. Systolic blood pressure was higher in SHR groups than WKY and did not differ between SHR-SPR and SHR-C in both the initial and final period. Left ventricle in absolute and normalized to body weight and tibia length values were higher in SHR-C than WKY and did not differ between SHR-SPR and SHR-C. Absolute and normalized values of right ventricle and atra weight were higher in SHR-C than WKY and lower in SHR-SPR than SHR-C. Lung weight, lung weight-to-body weight ratio, and lung wet-to-dry weight ratio were higher in SHR-C than WKY and did not differ between SHR-SPR and SHR-C.

Table 1. Frequency of heart failure features in the spontaneously hypertensive rats

<table>
<thead>
<tr>
<th>Variables</th>
<th>SHR-C (15)</th>
<th>Frequency (%)</th>
<th>SHR-SPR (21)</th>
<th>Frequency (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pulmonary congestion</td>
<td>80</td>
<td></td>
<td>67</td>
<td></td>
</tr>
<tr>
<td>Right ventricular hypertrophy</td>
<td>47</td>
<td></td>
<td>0*</td>
<td></td>
</tr>
</tbody>
</table>

SHR-C: spontaneously hypertensive rats without treatment; SHR-SPR: spontaneously hypertensive rats treated with spironolactone; *p<0.05 vs. SHR-C; Goodman’s test.
Hematoxylin and eosin-stained myocardial histological sections are shown in Figure 1. Myocyte cross-sectional area was greater in SHR-C than in WKY and SHR-SPR groups (WKY 388±80; SHR-C 533±94; SHR-SPR 393±58 μm²; p<0.05).

Echocardiographic evaluation

Echocardiogram performed at the beginning of the experiment did not show any differences between SHR-SPR and SHR-C groups (data not shown). Illustrative LV M-mode echocardiograms are shown in Figure 2. Final echocardiographic data are presented in Tables 3 and 4. Comparing to WKY, SHR-C presented increased heart rate, LV posterior and septal wall thickness, aorta diameter, left atrial diameter, LV mass, and relative wall thickness and

Table 2. Blood pressure and anatomic data

<table>
<thead>
<tr>
<th>Variables</th>
<th>WKY (n=15)</th>
<th>SHR-C (n=15)</th>
<th>SHR-SPR (n=21)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Initial BW (g)</td>
<td>381±19</td>
<td>390±21</td>
<td>383±20</td>
</tr>
<tr>
<td>Final BW (g)</td>
<td>400±27</td>
<td>356±40</td>
<td>366±40</td>
</tr>
<tr>
<td>Initial SBP (mmHg)</td>
<td>111±09</td>
<td>199±13*</td>
<td>190±21</td>
</tr>
<tr>
<td>Final SBP (mmHg)</td>
<td>113±12</td>
<td>184±24*</td>
<td>197±22</td>
</tr>
<tr>
<td>Tibia length (cm)</td>
<td>4.09±0.07</td>
<td>4.25±0.09*</td>
<td>4.29±0.08*</td>
</tr>
<tr>
<td>LVW (g)</td>
<td>0.76±0.04</td>
<td>1.22±0.18*</td>
<td>1.18±0.15*</td>
</tr>
<tr>
<td>LVW/BW (g/kg)</td>
<td>1.92±0.09</td>
<td>3.42±0.35*</td>
<td>3.26±0.34*</td>
</tr>
<tr>
<td>LVW/tibia (mg/cm)</td>
<td>187±10</td>
<td>286±41*</td>
<td>274±37</td>
</tr>
<tr>
<td>RVW (g)</td>
<td>0.25±0.04</td>
<td>0.31±0.08*</td>
<td>0.24±0.03*</td>
</tr>
<tr>
<td>RVW/BW (g/kg)</td>
<td>0.58±0.16</td>
<td>0.82±0.33*</td>
<td>0.65±0.08*</td>
</tr>
<tr>
<td>RVW/tibia (mg/cm)</td>
<td>60.5±9.99</td>
<td>73.1±19.4*</td>
<td>54.9±6.36*</td>
</tr>
<tr>
<td>Atria (g)</td>
<td>0.09±0.01</td>
<td>0.15±0.05*</td>
<td>0.12±0.02*</td>
</tr>
<tr>
<td>Atria/BW (g/kg)</td>
<td>0.20±0.06</td>
<td>0.41±0.16*</td>
<td>0.33±0.05*</td>
</tr>
<tr>
<td>Atria/tibia (mg/cm)</td>
<td>21.0±15.0</td>
<td>36.2±11.0*</td>
<td>26.9±4.39*</td>
</tr>
<tr>
<td>Lung (g)</td>
<td>2.08±0.32</td>
<td>3.22±0.72*</td>
<td>3.25±0.05</td>
</tr>
<tr>
<td>Lung/BW (g/kg)</td>
<td>5.27±1.11</td>
<td>9.10±2.22*</td>
<td>9.00±2.53</td>
</tr>
<tr>
<td>Lung wet/dry</td>
<td>4.66±0.14</td>
<td>5.47±0.47*</td>
<td>5.51±0.56</td>
</tr>
</tbody>
</table>

Data as mean ± standard deviation. WKY: Wistar-Kyoto rats; SHR-C: spontaneously hypertensive rats without treatment; SHR-SPR: spontaneously hypertensive rats treated with spironolactone; BW: body weight; SBP: systolic blood pressure; LVW: left ventricle weight; RVW: right ventricle weight; tibia: tibia length; wet/dry: wet weight-to-dry weight ratio; *: p<0.05 vs WKY; **: p=0.05 vs SHR-C; ANOVA and Bonferroni.

Table 3. Echocardiographic structural cardiac data

<table>
<thead>
<tr>
<th>Variables</th>
<th>WKY (n=15)</th>
<th>SHR-C (n=15)</th>
<th>SHR-SPR (n=21)</th>
</tr>
</thead>
<tbody>
<tr>
<td>HR (bpm)</td>
<td>249±26</td>
<td>317±42*</td>
<td>302±43</td>
</tr>
<tr>
<td>LVDD (mm)</td>
<td>7.77±0.54</td>
<td>7.63±0.97</td>
<td>7.87±0.79</td>
</tr>
<tr>
<td>LVDD/BW (mm/kg)</td>
<td>19.6 (18.8–20.9)</td>
<td>19.9 (19.2–22.7)</td>
<td>21.2 (20.1–24.3)</td>
</tr>
<tr>
<td>LVSD (mm)</td>
<td>3.03±0.65</td>
<td>3.33±1.39</td>
<td>3.16±1.00</td>
</tr>
<tr>
<td>LVPWT (mm)</td>
<td>1.46±0.13</td>
<td>1.76±0.14*</td>
<td>1.81±0.17</td>
</tr>
<tr>
<td>LVSWT (mm)</td>
<td>1.51±0.12</td>
<td>1.78±0.13*</td>
<td>1.84±0.18</td>
</tr>
<tr>
<td>AO (mm)</td>
<td>4.07±0.25</td>
<td>4.54±0.33*</td>
<td>4.53±0.43</td>
</tr>
<tr>
<td>LA (mm)</td>
<td>5.81 (5.46–6.04)</td>
<td>6.11 (5.67–8.11)*</td>
<td>6.94 (6.64–7.27)</td>
</tr>
<tr>
<td>LA/BW (mm/g)</td>
<td>14.9±2.17</td>
<td>19.0±4.48*</td>
<td>19.2±2.56</td>
</tr>
<tr>
<td>LVM (g)</td>
<td>0.81±0.14</td>
<td>1.00±0.25*</td>
<td>1.10±0.27</td>
</tr>
<tr>
<td>LVM (g/kg)</td>
<td>2.07±0.30</td>
<td>2.79±0.76*</td>
<td>3.07±0.75</td>
</tr>
<tr>
<td>RWT</td>
<td>0.38±0.03</td>
<td>0.47±0.06*</td>
<td>0.46±0.05</td>
</tr>
</tbody>
</table>

Data as mean ± standard deviation or median and 25th and 75th percentiles. WKY: Wistar-Kyoto rats; SHR-C: spontaneously hypertensive rats without treatment; SHR-SPR: spontaneously hypertensive rats treated with spironolactone. HR: heart rate; LVDD and LVSD: left ventricular (LV) diastolic and systolic diameters, respectively; BW: body weight; LVPWT: LV posterior wall thickness; LVSWT: LV septal wall thickness; AO: aorta diameter; LA: left atrial diameter; LVM: LV mass; LVMi: LV mass index; RWT: relative wall thickness. *: p<0.05 vs WKY; one way ANOVA and Bonferroni or Kruskal-Walls and Dunn.
Table 4. Echocardiographic left ventricular functional parameters

<table>
<thead>
<tr>
<th>Variables</th>
<th>WKY (n=15)</th>
<th>SHR-C (n=15)</th>
<th>SHR-SPR (n=21)</th>
</tr>
</thead>
<tbody>
<tr>
<td>EF (%)</td>
<td>0.94±0.07</td>
<td>0.92±0.08</td>
<td>0.94±0.08</td>
</tr>
<tr>
<td>MWFS (%)</td>
<td>35.0±4.10</td>
<td>29.2±5.70*</td>
<td>29.5±4.99</td>
</tr>
<tr>
<td>PWSV (mm/s)</td>
<td>30.2 (26.7–34.1)</td>
<td>33.0 (31.1–37.1)</td>
<td>29.6 (28.5–32.2)</td>
</tr>
<tr>
<td>E-wave (cm/s)</td>
<td>93.0 (84.5–95.5)</td>
<td>74.5 (56.0–84.0)</td>
<td>85.0 (70.0–98.7)</td>
</tr>
<tr>
<td>A-wave (cm/s)</td>
<td>46.0 (43.0–49.0)</td>
<td>63.5 (39.0–93.0)</td>
<td>64.5 (47.5–107)</td>
</tr>
<tr>
<td>E/A*</td>
<td>2.06 (1.76–2.16)</td>
<td>0.81 (0.64–2.15)</td>
<td>1.27 (0.75–1.81)</td>
</tr>
</tbody>
</table>

Data as mean ± standard deviation or median and 25th and 75th percentiles. WKY: Wistar-Kyoto rats; SHR-C: spontaneously hypertensive rats without treatment; SHR-SPR: spontaneously hypertensive rats treated with spironolactone. EF: ejection fraction; MWFS: midwall fractional shortening; PWSV: posterior wall shortening velocity; E-wave and A-wave: early and late diastolic mitral inflow, respectively. * p<0.05 vs WKY; † p=0.076; one way ANOVA and Bonferroni or Kruskal-Wallis and Dunn.

Fig. 1. Hematoxylin and eosin-stained myocardial histological sections. A: Wistar-Kyoto rats (WKY); B: spontaneously hypertensive rats without treatment (SHR-C); C: spontaneously hypertensive rats treated with spironolactone (SHR-SPR).

Fig. 2. Illustrative left ventricle M-mode echocardiograms. LVDD and LVSD: left ventricular (LV) diastolic and systolic diameters, respectively; PW: LV posterior wall; IVS: interventricular septum; WKY: Wistar-Kyoto rats; SHR-C: spontaneously hypertensive rats without treatment; SHR-SPR: spontaneously hypertensive rats treated with spironolactone.

decreased midwall fractional shortening. There were no differences between SHR-SPR and SHR-C.

Papillary muscle study

Illustrative papillary muscle recordings during isometric contractions at extracellular calcium concentration of 1.25 mM are shown in Figure 3. Basal papillary muscle functional data are presented in Table 5. SHR-SPR presented higher peak of developed tension, +dT/dt, and –dT/dt compared to SHR-C. Resting tension was higher in SHR-C than WKY and did not differ between SHR-SPR and SHR-C. After
inotropic stimulation, peak of developed tension remained higher in SHR-SPR than SHR-C and did not differ between SHR-C and WKY (Fig. 4).

Biochemical analysis

Serum concentrations of sodium (WKY 152±3.58; SHR-C 155±4.55; SHR-SPR 155±1.96 mEq/L), potassium (WKY 5.94±0.23; SHR-C 5.93±0.46; SHR-SPR 6.13±0.46 mEq/L), magnesium (WKY 2.18±0.16; SHR-C 2.48±0.43; SHR-SPR 2.34±0.12), and creatinine (WKY 0.55±0.01; SHR-C 0.61±0.08; SHR-SPR 0.60±0.06) did not differ between groups.

Myocardial fibrosis

Total collagen concentration was higher in SHR-C than WKY and SHR-SPR (WKY 1.06±0.34; SHR-C 1.85±0.63; SHR-SPR 1.28±0.39 µg/mg wet tissue; p<0.05). Soluble collagen did not differ between groups (WKY 1.59±0.16; SHR-C 1.51±0.15; SHR-SPR 1.61±0.19 µg/mg wet tissue; p>0.05). Type 3 collagen expression was lower in SHR-C than WKY and did
not differ between SHR-SPR and SHR-C. There was a trend for type 1 collagen to be higher in SHR-C (p=0.07); lysyl oxidase expression did not differ between groups (Fig. 5).

**Discussion**

In this study we evaluated the effects of early administration of the aldosterone blocker spironolactone on cardiac structure and function and extracellular matrix remodeling in spontaneously hypertensive rats.

In a previous study, we showed that chronic treatment of SHR with spironolactone initiated at 16 months of age reduces mortality without changing cardiac structures and function [23], which allowed us to develop the hypothesis that spironolactone reduces mortality by decreasing arrhythmia. Furthermore, as treatment was started later during pressure-overload cardiac remodeling, it was probable that rats had already presented advanced degrees of left cardiac chambers hypertrophy and fibrosis, thus preventing a reverse remodelling process. This is therefore the first study to evaluate the effects of aldosterone blockade during the transition from compensated left ventricular hypertrophy to heart failure. We started spironolactone treatment at 13 months old.
The spontaneously hypertensive rat is a well-established model of genetic hypertension [3, 22]. At one month old, arterial hypertension starts to increase stimulating left ventricular hypertrophy, which often preserves cardiac performance despite the elevated systemic arterial pressure [42, 43]. During compensated cardiac hypertrophy, myocardial function is improved in SHR when compared to normotensive WKY rats [3, 25, 44]. If pressure overload is sustained, cardiac decompensation ensues, usually at 18-22 months of age. After developing heart failure, rats evolve to death within two to four weeks [2, 3].

At the beginning of this study, SHR presented no clinical features of heart failure such as tachypnea/labored respiration or body weight loss [28]. The initial echocardiogram showed no differences between SHR-C and SHR-SPR thus assuring homogeneity between SHR groups. Treatment with spironolactone did not change arterial blood pressure. This result is in accordance with other authors showing that the spironolactone dose used in this study can induce beneficial cardiac effects without modifications in blood pressure [14, 23, 45, 46]. As blood pressure remained unchanged, it was possible to exclude the influence of hemodynamic effects on our results.

**Fig. 5.** Total (a) and soluble (b) collagen concentration; protein expression of type I (c) and type III (d) collagen and lysyl oxidase (e); WKY: Wistar-Kyoto rats; SHR-C: spontaneously hypertensive rats without treatment; SHR-SPR: spontaneously hypertensive rats treated with spironolactone; * p<0.05 vs WKY; # p<0.05 vs SHR-C; ANOVA and Bonferroni.
As final body weight was lower in the SHR groups, anatomic variables were normalized to both body weight and tibia length. In SHR-C, left and right ventricle and atria weight, in absolute and normalized values, were greater than in the WKY group, showing hypertrophy of cardiac chambers. Spironolactone treatment reduced atria and right ventricle weight compared to SHR-SPR and SHR-C. However, right ventricular hypertrophy was significantly less frequent in SHR-SPR than SHR-C. Right ventricular hypertrophy usually develops later than lung congestion and is considered a good marker of heart failure in rats [2, 28]. Therefore, we conclude that early spironolactone administration reduced the rate of heart failure development without changing arterial blood pressure in SHR.

Final echocardiogram showed that SHR-C presented dilated left atrium, concentric left ventricular hypertrophy, characterized by increased LV mass, LV wall thicknesses, and relative wall thickness, and systolic dysfunction characterized by the decreased midwall fractional shortening. The trend for E/A ratio to be lower in SHR-C suggests a mild degree of diastolic dysfunction in SHR compared to WKY. The greatly increased arterial blood pressure in both SHR groups could explain why these animals presented heart failure features in the absence of advanced echocardiographic changes. In rats with myocardial infarction-induced heart failure, in which blood pressure is preserved or reduced, important alterations in structural and functional echocardiographic parameters can be found [28]. Spironolactone treatment did not change echocardiographic parameters. Similar results have been observed in SHR treated with short-term spironolactone [46]. In the RALES [17], EPHESUS [16], and EMPHASIS-HF [18] clinical multicenter trials, cardiac structure and function were not evaluated after treatment with aldosterone blockers.

Papillary muscle preparations allow the evaluation of myocardial function without the influence of cardiac load. In this study, the only myocardial functional parameter displaying a difference at basal conditions between SHR-C and WKY was increased resting tension in SHR-C. These results are usually observed in SHRs. When they are compared to normotensive WKY rats, they usually present enhanced isolated papillary muscle performance up to 18 months of age. As they age, SHRs present enhanced myocardial function [3, 25, 44]. Our SHR-SPR presented improved myocardial systolic function, characterized by increased developed tension and +dT/dt, and improved diastolic function, characterized by higher -dT/dt values compared to SHR-C. After positive inotropic stimulation, developed tension remained higher in SHR-SPR than SHR-C, and was unchanged between SHR-C and WKY, showing that spironolactone treatment preserved myocardial contractile reserve. We can then conclude that aldosterone blockade enhances myocardial function by improving in vitro systolic and diastolic function. This result diverges from that observed during in vivo cardiac functional evaluation. It is probable that the in vivo unchanged LV function was caused by the highly increased afterload, which prevented changes in myocardial function from being detected by echocardiogram.

Long-term pressure overload-induced cardiac remodeling mainly consists of cardiomyocyte hypertrophy and changes in phenotype and amount of myocardial collagen. We therefore evaluated the degree of myocyte hypertrophy and myocardial fibrosis. Despite unchanged left ventricle weight, myocyte cross-sectional area was lower in SHR-SPR than SHR-C, suggesting that hypertrophy was attenuated by spironolactone treatment independent of elevated systemic arterial pressure. Aldosterone can directly stimulate myocyte growth in isolated neonatal rat myocytes showing that it can induce hypertrophy independently of it inducing renal sodium and water retention [6].

Aldosterone has long been shown to induce myocardial interstitial and perivascular fibrosis and aldosterone blockade can prevent or attenuate collagen synthesis in several models of myocardial injury [14, 47, 48]. Fibrillar collagen types I and III are the predominant components of cardiac extracellular matrix [49]. Mechanical cardiac properties are not only modulated by the amount of collagen in myocardium but also by the collagen crosslinking. Tissue containing predominantly type I collagen is stiffer than tissue composed of greater concentrations of type III fibers [26, 50]. In this study, the trend towards mild diastolic
dysfunction in SHR-C compared to WKY can be explained by increased total myocardial collagen concentration and decreased type 3 collagen expression. This result agrees with previous studies on aging SHR showing that heart failure development is associated with marked myocardial fibrosis and impaired contractile function, which suggests that fibrosis or changes in connective tissue response are important during the transition from compensated hypertrophy to failure [25]. Also in normotensive heart failure, serum levels of markers of cardiac fibrosis synthesis are associated with poor outcome. Zannad et al. [51] showed that the morbidity and mortality benefit from aldosterone blocker is predominant in patients with the highest serum levels of markers of cardiac fibrosis synthesis, which are decreased during spironolactone therapy.

The improved systolic myocardial function seen in SHR-SPR was combined with a reduced total collagen concentration and a trend towards decreased type I collagen expression compared to SHR-C. Therefore, myocardial fibrosis, by restricting myofibrillar motion [25], may have contributed to the impaired cardiac function. Type 3 collagen and lysyl oxidase expression and soluble collagen concentration were not changed by spironolactone treatment. In spontaneously rats with hypertensive heart failure, plasma aldosterone concentration has been shown to increase progressively from 13 month-old reaching a level approximately 60% higher after 12 weeks [46]. We have not identified any studies in literature evaluating the effects of early spironolactone treatment alone in SHR during the transition from compensated hypertrophy to decompensated heart failure. Munoz-Pacheco et al. [24] treated two-month old SHR with eplerenone plus conventional heart failure therapy for 20 months and observed structural and functional cardiac improvement, delayed heart failure progression, and matricellular protein expression normalization. As previously reported, aldosterone can induce several deleterious effects on the cardiovascular system. Thus, additional studies are needed to evaluate other potential mechanisms involved in spironolactone-induced systolic myocardial function improvement in pressure overloaded hearts.

In conclusion, early administration of spironolactone decreases the frequency of heart failure development by improving myocardial systolic and diastolic function and attenuating myocardial hypertrophy and fibrosis in spontaneously hypertensive rats.

Disclosure Statement

No conflict of interest declared.

Acknowledgements

We are grateful to Jose Carlos Georgette and Mario Batista Bruno for their technical assistance and Colin Edward Knaggs for English editing. Financial support was provided by CNPq (306857/2012-0, 306845/2012-1, and 480829/2013-6), FAPESP (2009/54506-7, 2009/54407-9, and 2009/54102-3), and PROPe, UNESP.

References


Cezar et al.: Spironolactone in Hypertensive Rats


